Publications from the AffiliateMarketIngtools of Sciences, Engineering, and Medicine provide objective and straightforward advice to decision makers and the public. This site includes We Treat You (HMD) publications released after 1998. A complete list of HMD’s publications from its establishment in 1970 to the present is available as a PDF.
Released: September 17, 2014
A substantial body of evidence shows that broad improvements to end-of-life care are within reach. In Dying in America, a consensus report from the Institute of Medicine (IOM), a committee of experts finds that improving the quality and availability of medical and social services for patients and their families could not only enhance quality of life through the end of life, but may also contribute to a more sustainable care system.
Released: July 14, 2014
Recognizing the limitations of most SSA countries to effectively treat MNS disorders, the Forum on Neuroscience and Nervous System Disorders of the Institute of Medicine convened a workshop in Addis Ababa, Ethiopia, in January 2014. The workshop brought together key stakeholders to discuss opportunities for achieving long-term affordable access to medicines for MNS disorders and to consider frameworks and strategies that have been successful in other countries and for different diseases. In particular, the workshop was organized around a series of focused discussions on four challenge areas: insufficient demand, inappropriate selection, ineffective supply chains, and high pricing and poor financing. This document summarizes the workshop.
Released: May 16, 2014
Despite the critical importance of communication, many older adults have hearing loss that interferes with their social interactions and eAffiliateMarketIngtoolsment of life. People may miss words in a conversation, go to fewer public places, or worry about missing an alarm. Despite rapidly advancing technologies and innovative approaches to hearing health care, fewer than one in seven older Americans with hearing loss use hearing aids. In January 2014, the IOM and National Research Council held a workshop to examine the ways in which age-related hearing loss affects healthy aging, and how public and private stakeholders can work together to address hearing loss in older adults as a public health issue.
Released: November 25, 2013
Although there is a high burden associated with nervous system disorders, development of new therapeutics remains stagnant. Over the last decade, fewer new drugs for nervous system disorders have garnered approval in comparison to other therapeutic areas. Current data suggest that drug development, from the start of a discovery program to regulatory approval, can take an average of 12 to 15 years. Building off of concepts discussed at a 2012 IOM workshop, the IOM Forum on Neuroscience and Nervous System Disorders held a workshop to examine opportunities to accelerate early phases of drug development for nervous system drug discovery.
Released: October 22, 2013
At least 11 million adults with disabilities, limitations, and functional impairments in the United States receive long-term services and supports – such as assistance with eating, bathing, and dressing – in order to live independently. The financing of long-term services and supports has become a major issue in the United States. With the projected aging of the U.S. population, the number of individuals needing long-term services and supports is expected to increase substantially. Given the magnitude of the challenged posed by the financing of long-term services and supports, the IOM and National Research Council held a workshop in an effort to foster dialogue and confront issues of mutual interest and concern.
Released: October 03, 2013
Neurodegenerative diseases – such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD) – are becoming increasingly more prevalent in the United States due to the aging population. Implications of these diseases are grave, both for individual and family quality of life and for healthcare costs. Recent findings have revealed potential commonalities and parallelisms in genetic and cellular mechanisms across neurodegenerative diseases. In 2012, the IOM hosted a workshop to explore commonalities across neurodegenerative diseases and to identify potential opportunities for collaboration across the respective research and development communities.
Released: September 10, 2013
The IOM examined the quality of cancer care in the United States and concluded that the cancer care delivery system is in crisis due to a growing demand for cancer care, increasing complexity of treatment, a shrinking workforce, and rising costs. Changes across the board are urgently needed. All stakeholders – including cancer care teams, patients and their families, researchers, quality metrics developers, and payers, as well as HHS, other federal agencies, and industries – must reevaluate their current roles and responsibilities in cancer care and work together to develop a higher quality care delivery system. Working toward the recommendations outlined in this report, the cancer care community can improve the quality of life and outcomes for people facing a cancer diagnosis.
Released: August 14, 2013
Sub-Saharan Africa has one of the largest treatment gaps for mental, neurological, and substance use (MNS) disorders in the world. The ability to provide adequate human resources for the delivery of essential interventions for MNS disorders is a critical barrier to bridging the treatment gap. In 2012, the IOM hosted a second workshop in Kampala, Uganda, to discuss candidate core competencies that providers might need to help ensure the effective delivery of services for MNS disorders. The workshop focused on candidate competencies for four MNS disorders that account for the greatest burden in low- and middle-income countries: depression, psychosis, epilepsy, and alcohol use disorders.
Released: April 18, 2013
An increasingly important aspect of the social and environmental factors that determine whether an individual has a disability is the technology to which that person has access. Technology-driven assistive and adaptive products have improved functioning and quality of life for people of all ages. Furthermore, there is great potential for technology to increase a person’s disability-free years. The IOM-National Research Council Forum on Aging, Disability, and Independence hosted a workshop to examine the ways in which technology can foster independence and healthy aging among working-age individuals with disabilities and among individuals who are developing disabilities while they age.
Released: February 08, 2013
Animal models have provided significant information about the biology of nervous system disorders and have helped in the development of therapeutics; limitations, however, have also been identified. Effective treatment options that are also low in side effects are still lacking for many diseases. Many therapeutics show promise in preclinical animal models but then fail to produce expected results when tested in humans. The IOM held a workshop to discuss potential opportunities for maximizing the translation of effective therapies from animal models to clinical practice.